Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30909263 | 1.00 | HTR1F (0.46) | HTR1FGRM4GRM1ALDH1A1KDM4E | |
| SCHEMBL8101018 | 0.87 | HTR1F (0.51) | HTR1FGRM4GRM1ALDH1A1KDM4E | |
| SCHEMBL30908928 | 0.87 | HTR1F (0.51) | HTR1FGRM4GRM1ALDH1A1KDM4E | |
| SCHEMBL8116660 | 0.86 | HTR1F (0.49) | HTR1FALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL30908942 | 0.86 | HTR1F (0.49) | HTR1FALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL8100851 | 0.83 | HTR1F (0.51) | HTR1FALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL8109534 | 0.78 | HTR1F (0.53) | HTR1FALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL30909215 | 0.76 | HTR1F (0.49) | HTR1FHTR1A | |
| SCHEMBL8114968 | 0.76 | HTR1F (0.49) | HTR1FHTR1A | |
| SCHEMBL8101122 | 0.73 | HTR1F (0.55) | HTR1FALDH1A1KDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| EP-0749962-B1 | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles | LILLY CO ELI (US) | 2000-11-02 | — | — | EP | disclosed |
| US-5814653-A | SUMATRIPTAN FOR RELIEF OF MIGRAINE PAIN AND OTHER DISORDERS ASSOCIATED WITH PEPTIDE EXTRAVASATION DIE TO STUMULATION OF THE TRIGEMINAL GANGLIA; 5-HT 1F AGONISTS | ELI LILLY AND COMPANY (US) | 1998-09-29 | — | — | US | disclosed |
| US-5708187-A | MIGRANE HEADACHES | ELI LILLY AND COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| EP-0749962-A1 | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles | ELI LILLY AND COMPANY (US) | 1996-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | HTR1F 1/4885GRM4 2280/4885GRM1 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.